CAMBRIDGE, Mass., Nov. 06, 2024 (GLOBE NEWSWIRE) — Fulcrum Therapeutics, Inc.® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced that its third quarter 2024 financial results will be released on Wednesday, November 13, 2024, before the U.S. financial markets open. Management will host a conference call and webcast at 8:00 a.m. ET to discuss the results and provide an update on recent corporate developments.
Individuals may register for the conference call by clicking the link here. Once registered, participants will receive dial-in details and unique PIN which will allow them to access the call. An audio webcast will be accessible through the Investor Relations section of the company’s website at www.fulcrumtx.com or by clicking here. Following the live webcast, an archived replay will also be available.
About Fulcrum Therapeutics
Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases in areas of high unmet medical need. Fulcrum’s lead program in clinical development is pociredir, a small molecule designed to increase expression of fetal hemoglobin and in development for the treatment of sickle cell disease (SCD). Fulcrum uses proprietary technology to identify drug targets that can modulate gene expression to treat the known root cause of gene mis-expression. For more information, visit www.fulcrumtx.com and follow us on Twitter/X (@FulcrumTx) and LinkedIn.
Contact:
Chris Calabrese
LifeSci Advisors, LLC
ccalabrese@lifesciadvisors.com
917-680-5608
Toronto, Ontario--(Newsfile Corp. - November 7, 2024) - HearAtLast Holdings, Inc. (OTC Pink: HRAL), is…
Alcaraz brings nearly 20 years of experience in quality management to the roleWest Caldwell, New…
Common Shares to Begin Trading on Nasdaq on Tuesday, November 12, 2024Vancouver, British Columbia and…
Vancouver, British Columbia--(Newsfile Corp. - November 7, 2024) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB:…
Halifax, Nova Scotia--(Newsfile Corp. - November 7, 2024) - Sona Nanotech Inc. (CSE: SONA) (OTCQB:…
Final step before the full launch of breast cancer screening program, Revealia™SPARKS, NV / ACCESSWIRE…